ARS Pharmaceuticals (SPRY) Net Cash Flow (2020 - 2026)

ARS Pharmaceuticals has reported Net Cash Flow for 7 years, with the latest figure at -$17.0 million in Q1 2026.

• Quarterly Net Cash Flow fell 55.17% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.5 million (up 3.71% YoY) and the FY2025 annual result came in at -$9.5 million, up 52.86% from the prior year.
• Net Cash Flow advanced to -$17.0 million in Q1 2026 per SPRY's latest filing, from -$18.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $173.2 million in Q4 2022 and troughed at -$122.7 million in Q1 2023.
• A 5-year average of -$2.1 million and a median of -$7.6 million in 2022 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 508.91% in 2023, down 1461.7% in 2023.
• Over 5 years, Net Cash Flow stood at $173.2 million in 2022, then tumbled by 93.97% to $10.4 million in 2023, then climbed by 6.91% to $11.2 million in 2024, then sank by 263.44% to -$18.2 million in 2025, then increased by 6.82% to -$17.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$17.0 million, -$18.2 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.